By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Problems with a reagent may have affected results from about 100 cancer diagnostics tests, Rosetta Genomics reported on Tuesday after the close of the market.

The affected test is the firm's miRview mets — a molecular test for cancer of unknown primary patients that identifies the tissue of origin of metastatic tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.